

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			Application N .	10/660,434
			Filing Date	September 10, 2003
			First Named Inventor	Guennadi V. Glinski
			Art Unit	Not yet known
			Examiner Name	Not yet known
			Attorney Docket Number	23543-07570
Sheet	1	of	2	

mailed 12/4/03

DEC 15 2003

U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Document Number – Kind Code <sup>2</sup> (if known)	Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		US-		

FOREIGN PATENT DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Number <sup>3</sup> – Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document

OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		
JL	C1	CLARK, E.A., et al., Genomic Analysis of Metastasis Reveals an Essential Role for RhoC, Nature, 2000, pp.532-535, volume 406.		
	C2	DHANASEKARAN, S.M., et al., Delineation Of Prognostic Biomarkers In Prostate Cancer, Nature, August 23, 2001, pp. 822-826, volume 412.		
	C3	FOROZAN, F., et al., Comparative Genomic Hybridization Analysis of 38 Breast Cancer Cell Lines: A Basis for Interpreting Complementary DNA Microarray Data, Cancer Research, 2000, pp. 4519-4525, volume 60.		
	C4	GLINSKY, G.V., et al., 2002 Microarray gene expression of tumor progression in the nude mouse model of human prostate cancer. In Proceedings of the 93 <sup>rd</sup> Annual Meeting of the American Association for Cancer Research, April 6-10, San Francisco, CA 43:462 (Abstract #4480).		
	C5	LUO, J., et al., Gene Expression Signature of Benign Prostatic Hyperplasia Revealed by cDNA Microarray Analysis, Prostate, 2002, pp.189-200, volume 51.		
	C6	LUO, J., et al., Human Prostate Cancer and Benign Prostatic Hyperplasia: Molecular Dissection By Gene Expression Profiling, Cancer Research, 2001, pp. 4683-4688, volume 61.		
	C7	MAGEE, J.A., et al., Expression Profiling Reveals Hepsin Overexpression In Prostate Cancer, Cancer Research, 2001, pp. 5692-5698, volume 61.		
	C8	NOTTERMAN, Daniel. A., et al., Transcriptional Gene Expression Profiles of Colorectal Adenoma, Adenocarcinoma, and Normal Tissue Examined of Oligonucleotide Arrays, Cancer Research, April 1, 2001, pp. 3124-3130, volume 61.		

Examiner Signature	/Jerry Lin/	Date Considered	06/14/2006
--------------------	-------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

23543/07570/DOCS/1395950.1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application N .	10/660,434
		Filing Date	September 10, 2003
		First Named Inventor	Guennadi V. Glinski
		Art Unit	Not yet known
		Examiner Name	Not yet known
Sheet 2 of 2	Attorney Docket Number	23543-07570	

DEC 15 2003

OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, series, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
JL	C9	PEROU, C.M., et al., Distinctive Gene Expression Patterns in Human Mammary Epithelial Cells and Breast Cancers, Proc. Natl. Acad. Sci. USA, 1999, pp. 9212-9217, volume 96.	
	C10	PEROU, C.M., et al., Molecular Portrait of Human Breast Tumors, Nature, 2000, pp. 747-752, volume 406.	
	C11	POZACK, J.R., et al., Genome-Wide Analysis of DNA-Copy Number Changes Using cDNA Microarrays, Nature Genetics, 1999, pp. 41-46, volume 23.	
	C12	RHODES, D.R., et al., Meta-analysis of Microarrays: Interstudy Validation of Gene Expression Profiles Reveals Pathways Dysregulation in Prostate Cancer, Cancer Research, 2002, pp. 4427-4433, volume 62.	
	C13	ROSS, Douglas T., et al., Systematic Variation in Gene Expression Patterns in Human Cancer Cell Lines, Nature Genetics, March 2000, pp. 227-235, volume 24.	
	C14	SINGH, D., et al., Gene Expression Correlates of Clinical Prostate Cancer Behavior, Cancer Cell, March 2002, pp. 203-209, volume 1.	
	C15	SØRLIE, Therese, et al., Gene Expression Patterns of Breast Carcinomas Distinguish Tumor Subclasses with Clinical Implications, Proc. Natl. Acad. Sci. USA, September 11, 2001, pp. 10869-10874, volume 98, number 19.	
	C16	STAMEY, T.A., et al., Molecular Genetic Profiling Of Gleason Grade 4/5 Prostate Cancers Compared to Benign Prostatic Hyperplasia, J.Urol., December 2001, pp. 2171-2177, volume 168(6).	
	C17	SU, Andrew I., et al., Molecular Classification of Human Carcinomas by Use of Gene Expression Signatures, Cancer Research, October 15, 2001, pp. 7388-7393, volume 61.	
	C18	VAN'T Veer, Laura J., et al., Gene Expression Profiling Predicts Clinical Outcome of Breast Cancer, Nature, January 31, 2002, pp. 530-536, volume 415.	
	C19	WELSH, J.B., et al., Analysis of Gene Expression Identifies Candidate Markers and Pharmacological Targets in Prostate Cancer, Cancer Research, 2001, pp. 5974-5978, volume 61.	
	C20	WELSH, J.B., et al., Analysis of Gene Expression Profiles in Normal and Neoplastic Ovarian Tissue Samples Identifies Candidate Molecular Markers of Epithelial Ovarian Cancer, Proc. Natl. Acad. Sci. USA, January 30, 2001, pp. 1176-1181, volume 98, number 3.	


Examiner Signature	/Jerry Lin/	Date Considered	06/14/2006
--------------------	-------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

23543/07570/DOCS/1395950.1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Substitute for form 1449A/PTO

Submitted 12/22/03

**Complete if Known**

Application N	10/660,434
Filing Date	September 10, 2003
First Named Inventor	Guennadi V. Glinskii
Art Unit	Not yet known 1651
Examiner Name	Not yet known
Attorney Docket Number	23543-07570

Sheet 1 of 2

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document No. Number - Kind Code <sup>2</sup> (if known)	Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		US-		

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T <sup>6</sup>

**OTHER REFERENCES - NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>6</sup>
JL	CA 21	BHATTACHARJEE, ARINDAM, et al.; Classification Of Human Lung Carcinomas By mRNA Expression Profiling Reveals Distinct Adenocarcinoma Subclasses; Proc. Natl. Acad. Sci.; November 20, 2001; pp. 13780-13795; vol. 98, no. 24.	
	C22	BUCKHAULTS; PHILLIP, et al.; Secreted And Cell Surface Genes Expressed In Benign And Malignant Colorectal Tumors; Cancer Research; October 1, 2001; pp. 6996-7001; vol. 61.	
	CA 23	FUJII, TAKESHI, et al.; A Preliminary Transcriptome Map Of Non-Small Cell Lung Cancer; Cancer Research; June 15, 2002; pp. 3340-3346; vol. 62.	
	CA 24	GIORDANO, THOMAS J., et al.; Short Communication: Organ-Specific Molecular Classification Of Primary Lung, Colon, And Ovarian Adenocarcinomas Using Gene Expression Profiles; American Journal of Pathology; October 2001; pp. 1231-1238; vol. 159, no. 4.	
	CA 25	GLINSKII, G.V., et al.; Microarray Gene Expression Analysis Of Tumor Progression In The Nude Mouse Model Of Human Prostate Cancer; In Proceedings of the 93 <sup>rd</sup> Annual Meeting for the American Association for Cancer Research; Abstract #4480; April 6-10, 2002; 43: 462.	
	CA 26	GORDON, GAVIN J., et al.; Translation Of Microarray Data Into Clinically Relevant Cancer Diagnostic Tests Using Gene Expression Ratios In Lung Cancer And Mesothelioma; Cancer Research; September 1, 2002; pp. 4963-4967; vol. 62.	
	CA 27	LATULIPPE, EVA, et al.; Comprehensive Gene Expression Analysis Of Prostate Cancer Reveals Distinct Transcriptional Programs Associated With Metastatic Disease; Cancer Research; August 1, 2002; pp. 4499-4506; vol. 62.	
	CA 28	MONNI, OUTI, et al.; Comprehensive Copy Number And Gene Expression Profiling Of The 17q23 Amplicon In Human	


Examiner Signature	/Jerry Lin/	Date Considered	06/14/2006
--------------------	-------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

23543/07570/DOCS/1399816.1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

submitted 12/22/03

## Complete if Known

Application No.	10/660,434
Filing Date	September 10, 2003
First Named Inventor	Guennadi V. Glinskii
Art Unit	Not yet known 1651
Examiner Name	Not yet known
Attorney Docket Number	23543-07570

Sheet 2 of 2

## OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
JL		Breast Cancer, Proc. Natl. Acad. Sci.; May 8, 2001; pp. 5711-5716; vol. 98, no. 10.	
	C8 <sup>29</sup>	MOUSSES, SPYRO, et al.; Clinical Validation Of Candidate Genes Associated With Prostate Cancer Progression In The CWR22 Model System Using Tissue Microarrays; Cancer Research; March 1, 2002; pp. 1256-1260; vol. 62.	
	C10 <sup>30</sup>	NARLA, GOUTHAM, et al., KLF6, A Candidate Tumor Suppressor Gene Mutated In Prostate Cancer; Science; December 21, 2001; pp. 2563-2568; vol. 294.	
	C11 <sup>31</sup>	RAMASWAMY, SRIDHAR, et al.; DNA Microarrays In Clinical Oncology; Journal of Clinical Oncology; April 1, 2002; pp. 1932-1941; vol. 20, no. 7.	
	C12 <sup>32</sup>	SAVERIO, BETTUZZI, et al.; Tumor Progression Is Accompanied By Significant Changes In The Levels Of Expression Of Polyamine Metabolism Regulatory Genes And Clusterin (Sulfated Glycoprotein 2) In Human Prostate Cancer Specimens; Cancer Research; January 1, 2000; pp. 28-34; vol. 60.	
	C13 <sup>33</sup>	SHOU, JIANYONG; et al.; Expression Profiling Of A Human Cell Line Model Of Prostatic Cancer Reveals A Direct Involvement Of Interferon Signaling In Prostate Tumor Progression; Proc. Natl. Acad. Sci.; March 5, 2002; pp. 2830-2835; vol. 99, no. 5.	
	C14 <sup>34</sup>	SU, ANDREW I.; et al.; Large-scale Analysis Of The Human And Mouse Transcriptomes; Proc. Natl. Acad. Sci.; April 2, 2002; pp. 4465-4470; vol. 99, no. 7.	
	C15 <sup>35</sup>	SUGITA, MICHIO, et al.; Combined Use Of Oligonucleotide And Tissue Microarrays Identifies Cancer/Testis Antigens As Biomarkers In Lung Carcinoma; Cancer Research; July 15, 2002; pp.3971-3979; vol. 62.	

Examiner Signature	/Jerry Lin/	Date Considered	06/14/2006
--------------------	-------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

23543/07570/DOCS/1399816.1

APR 15 2005

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			Application No.	10/660,434	
			Filing Date	September 10, 2003	
			First Named Inventor	Guennadi V. Glinskii	
			Art Unit	1651	
			Examiner Name	Unassigned	
Sheet	1	of	1	Attorney Docket Number	23543-07570US

*Submitted 4/15/05*

U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Document No. Number - Kind Code <sup>2</sup> (if known)	Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
JL		US-6,455,280 B1	09-24-2002	Edwards, et al.
		US-2002/0032319A1	03-14-2002	Cargill, et al.
		US-2002/0119451A1	08-29-2002	Usuka, et al.
		US-2003/0175961A1	09-18-2003	Herron

FOREIGN PATENT DOCUMENTS					
		Foreign Patent Document			
Examiner Initials*	Cite No. <sup>1</sup>	Country Code <sup>2</sup> – Number <sup>3</sup> Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T <sup>4</sup>

OTHER REFERENCES - NON-PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>4</sup>	
		PCT International Search Report for PCT Application No. PCT/US03/28707, dated March 10, 2005, 4 pages.		

Examiner Signature	/Jerry Lin/	Date Considered	06/14/2006
--------------------	-------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

23543/07570/SF/5141332.1

PTO/SB/08A (10-01)  
 Approved for use through 10/31/2002, OMB 0651-0031  
 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application No.	10/660,434
				Filing Date	September 10, 2003
				First Named Inventor	Guennadi V. Glinskii
				Art Unit	1651
				Examiner Name	Unassigned
Sheet	1	of	1	Attorney Docket Number	23543-07570US

*submitted 6/24/05*

U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Document No. Number - Kind Code <sup>2</sup> (if known)	Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
JL		US-6,506,594	01-2003	Barany, et al.
JL		US-6,451,525	09-2002	Blasband, et al.

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>2</sup> - Number Kind Code <sup>3</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T <sup>4</sup>

OTHER REFERENCES - NON-PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		T <sup>4</sup>

Examiner Signature	/Jerry Lin/	Date Considered	06/14/2006
--------------------	-------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608.  
 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

23543/07570/SF/5141332.2